消化系统肿瘤“免疫治疗前移”的探索

doi:10.11904/j.issn.1002-3070.2021.03.012

实用肿瘤学杂志 ›› 2021, Vol. 35 ›› Issue (3): 258-262.doi: 10.11904/j.issn.1002-3070.2021.03.012

消化系统肿瘤“免疫治疗前移”的探索

马明瑞, 连洁, 刘超, 娄长杰综述, 张艳桥审校

哈尔滨医科大学附属肿瘤医院消化肿瘤内科(哈尔滨 150081)

收稿日期:2020-06-15 修回日期:2020-09-08 出版日期:2021-06-28 发布日期:2021-06-22
通讯作者: 张艳桥,E-mail:yanqiaozhang@ems.hrbmu.edu.cn
作者简介:马明瑞,女,(1995-),硕士研究生,从事消化系统肿瘤的临床研究。
基金资助:
国家自然科学基金项目(编号:81872427)

Exploration of “immunotherapy moving forward” for digestive system tumors

MA Mingrui, LIAN Jie, LIU Chao, LOU Changjie, ZHANG Yanqiao

Department of Gartrointestinal Medical Oncology,Harbin Medical University Cancer Hospital,Harbin 150081,China

Received:2020-06-15 Revised:2020-09-08 Online:2021-06-28 Published:2021-06-22

摘要/Abstract

摘要： 免疫检查点抑制剂的出现为肿瘤治疗带来了新的曙光。免疫检查点抑制剂需要激活自身免疫对抗肿瘤细胞,因此,在患者免疫状态更好时使用免疫治疗可能会为患者带来更多获益。目前免疫治疗多用于肿瘤的后线治疗,但经过多线治疗的患者一般状态较差,免疫治疗的效果可能降低。“免疫治疗前移”指在肿瘤治疗的过程中前线应用免疫治疗,以期达到更好的治疗效果。本文就消化系统肿瘤中“免疫治疗前移”的背景、临床试验及待解决问题进行综述。

关键词: 消化系统肿瘤, 免疫检查点抑制剂, 免疫治疗

Abstract: The emergence of immunosuppressive checkpoint inhibitors has brought new hope for tumor treatment.Immune checkpoint inhibitors need to activate autoimmune anti-tumor cells,so immunotherapy may bring more benefits to patients when their immune status is better.At present,immunotherapy is mostly used for the posterior line treatment of tumor,but the patients after multi-line treatment are generally in poor condition,and the effect of immunotherapy may be reduced.“Immunotherapy forward” refers to the application of immunotherapy in the process of tumor treatment in order to achieve better therapeutic effects.This article reviews the background,clinical trials and problems to be solved of “immunotherapy forward” in digestive system tumors.

Key words: Digestive system tumor, Immune checkpoint inhibitors, Immunotherapy

中图分类号:

R735

马明瑞, 连洁, 刘超, 娄长杰, 张艳桥. 消化系统肿瘤“免疫治疗前移”的探索[J]. 实用肿瘤学杂志, 2021, 35(3): 258-262.

MA Mingrui, LIAN Jie, LIU Chao, LOU Changjie, ZHANG Yanqiao. Exploration of “immunotherapy moving forward” for digestive system tumors[J]. Journal of Practical Oncology, 2021, 35(3): 258-262.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2021.03.012

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2021/V35/I3/258

参考文献

1 Mattiuzzi C,Lippi G.Current cancer epidemiology[J].J Epidemiol Glob Health,2019,9(4):217-222.
2 Pardoll DM.The blockade of immune checkpoints in cancer immunotherapy[J].Nat Rev Cancer,2012,12(4):252-264.
3 Boussiotis VA,Chatterjee P,Li L.Biochemical signaling of PD-1 on T cells and its functional implications[J].Cancer J,2014,20(4):265-271.
4 Yao S,Zhu Y,Chen L.Advances in targeting cell surface signalling molecules for immune modulation[J].Nat Rev Drug Discov,2013,12(2):130-146.
5 Keung EZ,Ukponmwan EU,Cogdill AP,et al.The rationale and emerging use of neoadjuvant immune checkpoint blockade for solid malignancies[J].Ann Surg Oncol,2018,25(7):1814-1827.
6 Reck M,Rodríguez-Abreu D,Robinson AG,et al.Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer[J].N Engl J Med,2016,375(19):1823-1833.
7 Altundag K.Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer[J].N Engl J Med,2019,380(10):986-987.
8 王程浩,韩泳涛.2020年中国临床肿瘤学会《食管癌诊疗指南》解读[J].肿瘤预防与治疗,2020,33(4):285-290.
9 Hong MH,Kim HR,Park SY,et al.A phase Ⅱ trail of preoperative chemoradiotherapy and Pembrolizumab for locally advanced esophageal squamous cell carcinoma(ESCC)[J].J Clin Oncol,2019,37(15):4027.
10 Shapiro J,van Lanschot JJB,Hulshof MCCM,et al.Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer(CROSS):long-term results of a randomised controlled trial[J].Lancet Oncol,2015,16(9):1090-1098.
11 Zhang B,Qi L,Wang X,et al.Phase 2 study of camrelizumab(anti-PD-1 antibody)combined with apatinib and chemotherapy for the first-line treatment of advanced esophageal squamous cell carcinoma[J].J Clin Oncol,2019,37(15):4033.
12 闫滢,胡冰,王刚,等.紫杉醇联合奈达铂与奈达铂联合5-氟尿嘧啶作为一线方案治疗晚期食管鳞癌的对比研究[J].安徽医药,2011,15(11):1416-1417.
13 Kato K,Shah MA,Enzinger P,et al.KEYNOTE-590:Phase III study of first-line chemotherapy with or without Pembrolizumab for advanced esophageal cancer[J].Future Oncol,2019,15(10):1057-1066.
14 Vrána D,Matzenauer M,Melichar B.Current status of checkpoint inhibitors in the treatment of esophageal and gastric tumors-overview of studies[J].Klin Onkol,2017,31(1):35-39.
15 邱海波,周志伟.NCCN胃癌临床实践指南2017年第五版更新要点解读[J].中华胃肠外科杂志,2018,21(2):160-164.
16 Bang YJ,Kang YK,Catenacci DV,et al.Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma:results from the phase II nonrandomized KEYNOTE-059 study[J].Gastric Cancer,2019,22(4):828-837.
17 Tabernero J,Van Cutsem E,Bang Y,et al.Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction(G/GEJ)adenocarcinoma:the phase 3 KEYNOTE-062 study[J].Ann Oncol,2019,30(4):152-153.
18 Wang F,Wei XL,Wang FH,et al.Safety,efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab,a PD-1 antibody in phase Ib/II clinical trial NCT02915432[J].Ann Oncol,2019,30(9):1479-1486.
19 Bang YJ,Van Cutsem E,Fuchs CS,et al.KEYNOTE-585:phase III study of perioperative chemotherapy with or without Pembrolizumab for gastric cancer[J].Future Oncol,2019,15(9):943-952.
20 陈功.2017版美国国立综合癌症网络结直肠癌指南更新解读[J].中华胃肠外科杂志,2017,20(1):28-33.
21 Lenz HJ,Van Cutsem E,Limon ML,et al.Durable clinical benefit with Nivolumab(NIVO)plus low-dose Ipilimumab(IPI)as first-line therapy in microsatellite instability-high/mismatch repair deficient(MSI-H/dMMR)metastatic colorectal cancer(mCRC)[J].Ann Oncol,2018,29(8):714.
22 Chalabi M,Fanchi LF,Dijkstra KK,et al.Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers[J].Nat Med,2020,26(4):566-576.
23 Aglietta M,Barone C,Sawyer MB,et al.A phase I dose escalation trial of tremelimumab(CP-675,206)in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer[J].Ann Oncol,2014,25(9):1750-1755.
24 孟长婷.《2018年美国国立综合癌症网络胰腺癌临床实践指南(V2版)》更新要点及临床路径[J].临床肝胆病杂志,2018,34(11):2316-2323.
25 孙永琨.2018《CSCO原发性肝癌诊疗指南》解读-全身治疗部分[J].肝癌电子杂志,2018,5(3):11-14.
26 Kudo M.Extremely high objective response rate of lenvatinib:its clinical relevance and changing the treatment paradigm in hepatocellular carcinoma[J].Liver Cancer,2018,7(3):215-224.
27 Qin S,Cheng AL,Ducreux MP,et al.IMbrave150:a randomised phase III study of atezolizumab+bevacizumab vs.sorafenib in locally advanced or metastatic hepatocellular carcinoma[J].Ann Oncol,2018,29(9):66.

[1]	王萌萌, 连洁, 李恒震, 张艳桥. 胃肠胰神经内分泌肿瘤的免疫治疗研究进展[J]. 实用肿瘤学杂志, 2021, 35(2): 154-159.
[2]	王明明, 陈晓品. 抗PD-1/PD-L1和CTLA-4免疫治疗在头颈鳞癌中的研究进展[J]. 实用肿瘤学杂志, 2021, 35(2): 179-183.
[3]	李瑞阳,方琳(综述),张艳桥(审校). 食管癌免疫治疗研究进展[J]. 实用肿瘤学杂志, 2021, 35(1): 41-45.
[4]	刘学静(综述),徐燕颖(审校). B7-H6在恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2021, 35(1): 46-49.
[5]	张璐,陆静钰(综述),陆海军(审校). 头颈部鳞癌相关生物标志物与免疫治疗预后的关系[J]. 实用肿瘤学杂志, 2021, 35(1): 55-58.
[6]	石琳娜, 隋红. 原发性肝癌免疫检查点抑制剂治疗的进展与挑战[J]. 实用肿瘤学杂志, 2020, 34(6): 560-564.
[7]	范晓娜, 王丹, 黎清炜, 李志伟. 胰腺癌术后辅助药物治疗的研究进展[J]. 实用肿瘤学杂志, 2020, 34(3): 249-253.
[8]	侯建英, 朱巍. 免疫抑制剂PD-1/PD-L1治疗卵巢癌的研究进展[J]. 实用肿瘤学杂志, 2020, 34(3): 266-270.
[9]	刘超, 郑桐森. 新冠肺炎时期肿瘤内科工作的总结和反思[J]. 实用肿瘤学杂志, 2020, 34(2): 100-102.
[10]	曹涤非, 黄国庆, 薛佳莹, 吴琼, 王雷, 李瑶. CA153在乳腺癌免疫治疗中的作用[J]. 实用肿瘤学杂志, 2019, 33(6): 566-569.
[11]	姚洋张艳桥. 胃癌免疫检查点抑制剂作用机制及最新研究进展[J]. 实用肿瘤学杂志, 2019, 33(4): 371-375.
[12]	韩帮岭, 汪亦民综述, 薛英威审校. 维生素D在消化系统肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(5): 471-475.
[13]	孙祖刚, 王哲, 陈怀安, 刘硕, 苗文隆. 诱发膀胱癌的常见慢性炎症因素及其免疫治疗的研究进展[J]. 实用肿瘤学杂志, 2018, 32(4): 357-361.
[14]	张婷, 贾迪(综述), 杨丹(审校). 骨肉瘤的生物学治疗进展[J]. 实用肿瘤学杂志, 2018, 32(3): 254-257.
[15]	苗素平, 郭二亮, 裴荣, 姜寰宇, 苗素生. miRNA调节免疫检查点在肿瘤治疗中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(1): 57-62.

消化系统肿瘤“免疫治疗前移”的探索

Exploration of “immunotherapy moving forward” for digestive system tumors

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价